If the weight maintenance observed in these preclinical studies is validated in humans, TIX100 could become a novel, non-GLP-1 option to support sustained weight management after medical weight loss intervention, addressing this important unmet need in the treatment of overweight and obesity, Shalev said
Someone spending $40 a month on patches instead of consulting a healthcare provider about evidence-based options is losing time during which effective treatment could be producing results
It began July 1, 2026, and allows eligible Part D beneficiaries to get access to weight-loss GLP-1s for a flat $50 a month
British journal of community nursing, Suppl, S6S11
However, they also show that skin-related adverse events do occur and may be underrecognized in clinical practice. The reactions reported, she added, ranged from relatively mild findings to less common but more significant skin reactions